Highlights & Insights

Medicaid, once considered the ugly duckling compared with the politically powerful and popular Medicare program, now covers nearly 1 in 4 Americans.

Some recent key findings on the American public’s experience with and perceptions of prescription drugs and their prices.

This analysis examines U.S. Medicaid outpatient prescription drug utilization and spending before rebates over the 2015 to 2019 period, which is helpful for understanding recent cost drivers and areas for targeted policy action.

Recommendations on value assessment and funding processes in rare diseases.

American state-lawmakers have tried to lower high drug prices from nearly every angle. And, nearly every proposal has failed. Here's one reason why.

Europe is the second largest biopharmaceutical market in the world, with the 28 European Union (EU) countries accounting for $211 billion (18 per cent) of the total $1,133 billion market in 2018.

Countries that have enacted data exclusivity into their intellectual property laws have faced increased pharmaceutical import prices over the past 20 years.

An update of the global cancer cell therapy pipeline, including top agents and targets, the status of clinical trials, and real-world data evidencing their current use in clinical practice.

Americans just are not buying the claim that attempts to reign in drug prices will stifle innovation and devastate the pharmaceutical industry.

To control prescription drug costs, some U.S. policymakers have proposed external reference pricing (ERP), which would tie prices for high-cost drugs to those in other countries.

As of late April, over 1 billion COVID vaccine doses had been given to 570 million people. But who got them?

India is currently at the epicenter of the global coronavirus pandemic — but it is not the only country with a worsening Covid-19 outbreak.